Please provide your email address to receive an email when new articles are posted on . Overall, 56% of participants had a lupus nephritis class change on repeat biopsy. Of patients with initial ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Glomerular disease in LN is a dynamic process with the potential for glomerular lesions to transform from one pattern to another. 1-4 Adjacent glomeruli may show different degrees of involvement. The ...

Credit: Getty Images The full recommendations are a follow-up to the summary released during the ACR Convergence 2024 and is the first lupus nephritis guideline since 2012. The full lupus nephritis ...

CHICAGO — The current recommended benchmark for when to biopsy the kidney in patients with systemic lupus erythematosus (SLE) is arbitrary and results in missing the lupus nephritis (LN) cases that a ...

WASHINGTON — An investigational 12-protein panel of urinary biomarkers predicted histologically active lupus nephritis (LN) with 86% accuracy, according to research presented at the American College ...

In this video, Craig Gordon, MD, nephrologist at Tufts Medical Center and associate professor of medicine at Tufts University School of Medicine, discusses baseline characteristics in a case of lupus ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.